BOVen in 1L TP53mut MCL
BOVen: Phase II Trial of Zanubrutinib, Obinutuzmab, and Venetoclax in Treatment-Naive TP53-Mutated Mantle Cell Lymphoma

Released: December 14, 2023

Activity

Progress
1
Course Completed